Article

Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling

2021-09-30

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Resistance to standard therapy is a major reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Developing novel therapy to overcome PDAC drug-resistance is urgently needed. CRABP-II was highly expressed in all PDAC but not expressed in normal pancreatic tissues and chronic pancreatitis. CRABP-II was shown to promote PDAC migration and metast...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fa704d84-de27-5edd-a71b-7891628f6b9e
DOI: 10.21203/rs.3.rs-929878/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival SignalingDOI 10.21203/rs.3.rs-929878/v1Read

Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistanceSemantic proximity Read

Transcriptomic and functional analysis of <i>ANGPTL4</i> overexpression in pancreatic cancer nominates targets that reverse chemoresistanceSemantic proximity Read

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis.Semantic proximity Read

Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways.Semantic proximity Read

Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma.Semantic proximity Read

Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Semantic proximity Read

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaSemantic proximity Read

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.Semantic proximity Read

Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21Semantic proximity Read